중독·부작용 | Cases and Studies of Addiction & Disorder in Lottery & Gambling | 中毒 & 疾病
- date : 2015-05-20 01:10|hit : 2179
-
- Article] Quality of life in cervical cancer survivors: Patient and provider perspectives on common complications of cervical cancer and treatment
-
DocNo of ILP: 1434
Doc. Type: Article
Title: Quality of life in cervical cancer survivors: Patient and provider perspectives on common complications of cervical cancer and treatment
Authors: Einstein, MH; Rash, JK; Chappell, RJ; Swietlik, JM; Hollenberg, JP; Connor, JP
Full Name of Authors: Einstein, M. Heather; Rash, Joanne K.; Chappell, Richard J.; Swietlik, Jacquelyn M.; Hollenberg, James P.; Connor, Joseph P.
Keywords by Author: Early cervical cancer; Utilities; Complications; Chemoradiation; Surgery
Keywords Plus: GYNECOLOGIC-ONCOLOGY-GROUP; PELVIC RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; RADICAL HYSTERECTOMY; RANDOMIZED-TRIAL; CARCINOMA; STAGE; SURGERY; PERCEPTIONS; IRRADIATION
Abstract: Objective. This study's objective was to quantify the impact (utility) of common complications of early cervical cancer treatment on quality of life (QOL). Utilities assigned by survivors were compared to those assigned by providers. Methods. 30 survivors of early cervical cancer identified from our Tumor Registry and 10 gynecologic oncology providers were interviewed. Participants evaluated complications (health states) using the standard gamble (SG) and visual analogue scale (VAS). Each participant was randomly assigned to rate 5 of 13 health states. Mixed-effects linear models were used to generate confidence intervals for utility means, and evaluate the effect of group (survivors versus providers). Higher utilities indicate the health state is closer to perfect health. Results. Survivors and providers mean ages were similar (44 and 40). Mean time from diagnosis was 6.7 years. 28 of 30 survivors had no evidence of disease. 56% of survivors had complications. Using SG, providers consistently assigned utilities 7% higher than survivors (p = 0.035) for all health states except "ileostomy", which survivors rated higher than providers. Survivors assigned the lowest utility to small bowel obstruction (SBO) (fixable without an ostomy) and ureteral obstruction (UO). Survivors rated SBO 16% and UO 21% lower than providers. Personal history of complications or higher stage did not have a consistent effect on QOL adjustments. Discussion. Providers assign higher utilities than survivors to health states. Providers and survivors diverge on which complications impact QOL the most. Data on patient preferences should be considered when weighing treatment options with similar survival but different associated complications. (C) 2011 Elsevier Inc. All rights reserved.
Cate of OECD: Clinical medicine
Year of Publication: 2012
Business Area: other
Detail Business: medicine & science
Country: USA
Study Area:
Name of Journal: GYNECOLOGIC ONCOLOGY
Language: English
Country of Authors: [Einstein, M. Heather; Rash, Joanne K.; Swietlik, Jacquelyn M.; Connor, Joseph P.] Univ Wisconsin, Dept Obstet & Gynecol, Div Gynecol Oncol, Madison, WI 53706 USA; [Chappell, Richard J.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Hollenberg, James P.] Weill Cornell Med Coll, Dept Med, New York, NY USA
Press Adress: Einstein, MH (reprint author), Hartford Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, 85 Seymour St,Suite 705, Hartford, CT 06106 USA.
Email Address: heinstein@harthosp.org
Citaion:
Funding:
Lists of Citation: Ashing-Giwa KT, 2009, GYNECOL ONCOL, V112, P358, DOI 10.1016/j.ygyno.2008.11.002; Bergmark K, 1999, NEW ENGL J MED, V340, P1383, DOI 10.1056/NEJM199905063401802; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; Bruera E, 2002, CANCER, V94, P2076, DOI 10.1002/cncr.10393; Calhoun EA, 1998, GYNECOL ONCOL, V71, P369, DOI 10.1006/gyno.1998.5189; Eifel PJ, 2004, J CLIN ONCOL, V22, P872, DOI 10.1200/JCO.2004.07.197; Frumovitz M, 2005, J CLIN ONCOL, V23, P7428, DOI 10.1200/JCO.2004.00.399; Gold M, 1996, COST EFFECTIVENESS H; Gotay CC, 2008, MIL MED, V173, P1035; Greimel E, 2002, GYNECOL ONCOL, V85, P140, DOI 10.1006/gyno.2002.6586; Havrilesky LJ, 2009, GYNECOL ONCOL, V113, P216, DOI 10.1016/j.ygyno.2008.12.026; Jewell EL, 2007, GYNECOL ONCOL, V107, P532, DOI 10.1016/j.ygyno.2007.08.056; Landoni F, 1997, LANCET, V350, P535, DOI 10.1016/S0140-6736(97)02250-2; Landoni F, 2001, GYNECOL ONCOL, V80, P3, DOI 10.1006/gyno.2000.6010; Montgomery AA, 2001, QUAL HEALTH CARE, V10, pI39; Perez CA, 1999, INT J RADIAT ONCOL, V44, P855, DOI 10.1016/S0360-3016(99)00111-X; Peters WA, 2000, J CLIN ONCOL, V18, P1606; Rotman M, 2006, INT J RADIAT ONCOL, V65, P169, DOI 10.1016/j.ijrobp.2005.10.019; Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387; SLEVIN ML, 1990, BRIT MED J, V300, P1458; Stehman FB, 2007, AM J OBSTET GYNECOL, V197, pc1
Number of Citaion: 21
Publication: ACADEMIC PRESS INC ELSEVIER SCIENCE
City of Publication: SAN DIEGO
Address of Publication: 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
ISSN: 0090-8258
29-Character Source Abbreviation: GYNECOL ONCOL
ISO Source Abbreviation: Gynecol. Oncol.
Volume: 125
Version: 1
Start of File: 163
End of File: 167
DOI: 10.1016/j.ygyno.2011.10.033
Number of Pages: 5
Web of Science Category: Oncology; Obstetrics & Gynecology
Subject Category: Oncology; Obstetrics & Gynecology
Document Delivery Number: 913LO
Unique Article Identifier: WOS:000301879600030
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 20:21:01 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next